Navigation Links
Ranbaxy Labs Extends Roots in South Africa

In line with Ranbaxy Laboratories aggressive international expansion strategy, the approval from South Africa's Competition Commission has solidified the acquisition of Be-Tabs Pharmaceuticals (Pty) Limited ("Be-Tabs") by Ranbaxy Laboratories. (RNBV).

The deal is valued at R500 million (USD 70 Million) and will make Ranbaxy the fifth largest generic pharmaceutical company in South Africa.

Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 9 countries.

As part of this acquisition, Ranbaxy has concluded a Black Empowerment transaction with a Community Investment Holding(CIH) group company.

Peter Burema, President of Ranbaxy's global pharmaceutical division, who signed the deal on Friday 4th May said," the acquisition of Be-Tabs will ensure that Ranbaxy develops deeper roots in SA and with a strong local flavor."

A key element of the Be-Tabs deal is that it gives Ranbaxy local manufacturing capability - making the company one of the few generics pharmaceutical companies to invest in and develop local manufacturing functionality.

Desmond Brothers, CEO of Ranbaxy South Africa, says: "the company's decision to manufacture locally will not only help to provide quality medicine at a n affordable price to the Southern African market, but will also mean a further investment of approximately R100 million in the local economy."

Ranbaxy is also planning a major upgrade of the Be-Tabs manufacturing facility to bring its factories in line with new standards. With the re-vamp of the Be-Tabs facilities, the company expects to lead the way for generics manufacturing in South Africa. The acquisition of Be-Tabs substantially strengthens the basket of products that Ranbaxy brings to the market - especially in the acute and over the counter product streams. The company expects to use the brand equity that Be-Tabs has acquired to leverage market share among wholesalers, pharmacies, dispensing doctors and consumers.

Ranjan Chakravarti, Ranbaxy's Regional Director Africa and Latin America, added: "Ranbaxy entered South Africa with a business model that aimed to meet the country's need for access to affordable healthcare for a wide cross-section of the population. This acquisition - with its market presence and substantive manufacturing capabilities - is another step towards achieving this goal. "

Ranbaxy established a presence in South Africa in 1996 and has been rewarded with excellent growth in the past decade. The acquisition of Be-Tabs is expected to boost earnings by more than double.

Be-Tabs Pharmaceuticals (Pty) Ltd is the largest manufacturer of Penicillin formulations in South Africa and markets & manufactures a portfolio of ethical and over-the-counter (OTC) solid-oral and liquid formulations in South Africa. The Company actively participates in local and export tenders in the African Continent. With sales of approximately USD 30 Million, Be-Tabs is the fifth largest generic company in South Africa and one of the most profitable companies in the market. Be-Tabs Pharmaceuticals (Pty) Ltd was founded in Johannesburg, South Africa, in 1974 and focuses on producing the highest quality products in a co mpetitive pharmaceutical environment. Since its early beginnings, the Company has established itself as a dynamic pharmaceutical house with the object of serving South Africa and the neighboring countries with the best service and products possible.

Be-Tabs will remain an independent trading entity and will form one of the three companies within the Ranbaxy SA Group - the other two being Sonke Pharmaceuticals and Ranbaxy (S.A.) (Pty) Ltd.


'"/>




Related medicine news :

1. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
2. Ranbaxy gets US FDA approval for Lisinopril
3. Ranbaxy Labs Entry Into Anti-Acne Market
4. Ranbaxy trying to make inroads in herbal drugs market
5. Lamivudine Manufactured By Ranbaxy gets the nod from the US FDA
6. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
7. Ranbaxy opens Drug discovery centre in Gurgaon
8. Ranbaxy Laboratories All Set To Export Bird Flu Vaccines
9. SRL Ranbaxy offers quicker bird flu diagnostic test
10. Diagnostic Test Launched by Ranbaxy for En Masse Screening of Bird Flu
11. Ranbaxy Launches Once-a-day Inhaler For Asthma Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... ... 27, 2017 , ... Buzzies parent company, The TouchPoint Solution’s CEO and co-founder, ... and UBS’ Project Entrepreneur. Mayo will present her pitch about the lifestyle wearable devices, ... second annual venture competition ignites bold ideas by providing women access to the tools, ...
(Date:3/27/2017)... ... March 27, 2017 , ... American Veterinarian™, the leading multimedia ... medicine, announces the launch of Veterinarian’s Money Digest™, a business and financial resource ... of American Veterinarian™. , “We look forward to launching Veterinarian’s Money ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... products enables researchers to pursue the recent RNA methylation “gold rush” with their ... light of the newfound characteristics of N6-methyladenosine, or m6A , RNA methylation ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... According to ... prostate cancer, including all stages, is more than 95%. Once the cancer spreads to ... less than 30%. To find out how to avoid this latter group, tune in ...
(Date:3/27/2017)... ... March 27, 2017 , ... ?Grow Healthy Vending ... the pending litigation between itself and 1800 Vending DBA Healthy You Vending. (Civil ... am thrilled to announce that we have now reached a settlement agreement regarding ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017  Twist Bioscience, a ... synthesis, today announced that it raised an additional $33 ... of $166 million. "It is an ... expand our reach and continue to deliver industry-leading gene ... market segments," commented Emily M. Leproust, Ph.D., CEO of ...
(Date:3/27/2017)... 2017 Cota Healthcare, the leading ... medicine, today announced the signing of a ... to help improve clinical and cost outcomes ... part of this agreement, which expands significantly ... January 2016, teams from across Novartis Pharmaceuticals ...
(Date:3/27/2017)...   Genprex, Inc. , a privately held, clinical-stage biopharmaceutical company ... the Company,s Chief Operating Officer, is scheduled to present a corporate ... 5th Annual Cancer BioPartnering & Investment Forum: Tuesday, March 28, 2017 ... ... 24th Annual Future Leaders in Biotech Industry – Friday, April 7, ...
Breaking Medicine Technology: